Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating

Cathie Wood's Ark Investment Management holds $362 million in CRISPR Therapeutics across two ETFs. While known for gene-editing work like the FDA-approved Casgevy, the company is quietly developing CAR T-cell therapies that could address a market projected to exceed $60 billion annually by 2034. CRISPR's off-the-shelf CAR T approach using donor cells could reduce costs compared to patient-specific treatments, positioning it competitively despite being in early trial stages.